Table 5.

The roles of capecitabine, olaparib, and pembrolizumab in the adjuvant therapy of TNBC, examining both supporting and opposing trial data

Therapy	Supporting trials	Findings	Opposing trials	Concerns
Capecitabine	CREATE-X	Improved DFS and OS in residual disease post-neoadjuvant chemotherapy	Various smaller studies	Inconsistent benefits in different patient subsets
Olaparib	OlympiA	Improved DFS and OS in germline BRCA-mutated patients	None explicitly opposing efficacy	Long-term toxicity, cost-effectiveness, limited to BRCA mutations
Pembrolizumab	KEYNOTE-522	Improved pCR rates and EFS when combined with neoadjuvant chemotherapy	Long-term benefit unclear	Significant immune-related adverse events